Business Wire
-
Spectrum Pharmaceuticals To Present At The Rodman & Renshaw 10th Annual Global Healthcare Investment Conference
11/5/2008
Spectrum Pharmaceuticals, Inc., announced today that an overview of the Company’s business strategy will be presented at the Rodman & Renshaw Annual 10th Annual Global Healthcare Investment Conference, on Tuesday, November 11, 2008, at 12:00 p.m. Eastern
-
AgilityBio And Advinus Announce Partnership To Introduce Digital Pathology Services In Pre Clinical Research
11/5/2008
AgilityBio, a division of BioImagene Inc, and Advinus Therapeutics, a TATA enterprise, announced a partnership that will enable providing imaging services in conjunction with preclinical development services offered by Advinus
-
Progenics Selects Small-Molecule Hepatitis C Drug Candidate For Clinical Development
11/4/2008
Progenics Pharmaceuticals, Inc.,today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection
-
Akorn, Inc. Announces FDA Approval Of Adenosine Injection USP, 3 mg/mL
11/3/2008
Akorn, Inc., today announced that the U.S. Food and Drug Administration has granted approval for Akorn’s Abbreviated New Drug Application (ANDA) for Adenosine Injection USP, 3 mg/mL
-
Tripos International Completes Acquisition Of Pharsight Corporation
11/3/2008
Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development
-
Aureus Pharma To Participate In A European Consortium For Drug Cardiac Toxicity
10/30/2008
Aureus Pharma, a leading provider of knowledge management solutions that accelerate life science discovery, announced today that they will participate in a consortium along with a number of industrial and academic research teams in a European Commission funded project entitled “preDiCT: Computational Prediction of Drug Cardiac Toxicity”
-
National Cancer Institute Selects CambridgeSoft To Support Chemical Biology Consortium
9/29/2008
The National Cancer Institute has selected the ChemBioOffice Enterprise suite as the single solution Informatics platform to support a highly collaborative drug discovery partnership, the Chemical Biology Consortium
-
ACADIA Pharmaceuticals To Present At The JMP Securities Healthcare Focus Conference On October 6, 2008
9/29/2008
ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 1:00 p.m
-
Drug Discovery Research Turns To Biomarkers
9/25/2008
The total drug discovery market in Western Europe was worth $17.40 billion in 2007, and Frost & Sullivan expects this to grow at a compound annual growth rate of 13.5% to reach $42.08 billion by 2014
-
Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of CUDC-101
8/26/2008
Curis, Inc.a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor
This website uses cookies to ensure you get the best experience on our website. Learn more